Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brivaracetam Monotherapy Conversion in Partial Onset Seizures
NCT00698581Phase 3Terminated
- Sponsor
- UCB
- Start
- Aug 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of brivaracetam in epilepsy (2 arms), sponsored by UCB. Primary endpoint: The Cumulative Exit Rate at 112 Days After the Beginning of the Baseline Antiepileptic Drug (AED) Tapering Phase. Started Aug 2008; status: terminated.
02
Drugs
brivaracetam
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT00698581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00698581.